Find in Library

Diabetes is an independent risk factor for coronary heart disease, and the two are mutually causal in disease progression. Sodium-glucose cotransporter 2 inhibitor is a new oral medicine for the treatment of type 2 diabetes mellitus, which can play a hypoglycemic effect by blocking the reabsorption of glucose by the renal proximal convoluted tubules and increasing the excretion of urine glucose. A large number of studies have confirmed that in addition to hypoglycemic effects, SGLT2 inhibitors can also benefit in the treatment of coronary heart disease. This article mainly reviews the research progress and mechanism of SGLT2 inhibitors in the treatment of T2DM complicated with coronary heart disease.